NRGN and Alzheimer disease: A robust increase of CSF neurogranin in AD and mild cognitive impairment (MCI) because of AD (MCI–AD) compared with cognitively normal controls or cognitively stable MCI as well as MCI patients (78, 79) compared with controls or non-AD dementia patients (80) was found.